EHA: Cerdulatinib demonstrates rapid tumour responses in a phase 2 study for relapsed/refractory NHL
Cerdulatinib is an oral, dual Syk-JAK inhibitor with a unique mechanism of action. It inhibits…
Browsing: EHA Congress 2017
EHA: Delayed exposure to common infections causes acute leukaemia of childhood
Acute leukaemia is the most common cancer in childhood and the incidence is increasing especially…
EHA: Early metabolic response determination by FDG-PET allows substantial reduction of chemo and toxicity for advanced stage Hodgkin lymphoma
Hodgkin lymphoma is the most common malignancy of young adults. Intensive chemotherapy with 8 or…
EHA: Bleeding or clotting in elderly patients with cancer-associated venous thromboembolism: which is worse?
The risk of blood clots in the veins of the legs or the lungs, known…